Sterling Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Sterling Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.3K	Sell	924 -541	-37%	-$5.27K	﹤0.01%	2111
2026 Q1	$13.6K	Sell	1,465 -861	-37%	-$7.49K	﹤0.01%	2212
2025 Q4	$17.4K	Sell	2,326 -445	-16%	-$4.51K	﹤0.01%	2305
2025 Q3	$24.1K	Buy	2,771 +1,687	+156%	+$10.1K	﹤0.01%	2057
2025 Q2	$4.02K	Buy	1,084 +778	+254%	+$2.73K	﹤0.01%	2630
2025 Q1	$988	Sell	306 -329	-52%	-$1.55K	﹤0.01%	2822
2024 Q4	$3.54K	Buy	635 +546	+613%	+$4.29K	﹤0.01%	2596
2024 Q3	$962	Buy	+89	New	+$1.48K	﹤0.01%	2550

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Sterling Capital Management's FDMT Position: Q2 2026 in Review

Sterling Capital Management reduced its 4D Molecular Therapeutics (FDMT) stake by 37% in Q2 2026, selling an estimated $5.27K and leaving 924 shares worth $12.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2111.

Sterling Capital Management first reported a position in FDMT in Q3 2024 and has held it in 8 quarters since. The position peaked at $24.1K in Q3 2025. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Sterling Capital Management held 924 shares of 4D Molecular Therapeutics worth $12.3K as of Q2 2026.
Sterling Capital Management sold 541 4D Molecular Therapeutics shares in Q2 2026, an estimated $5.27K.
4D Molecular Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2111 holding.
Sterling Capital Management first reported a position in 4D Molecular Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's 4D Molecular Therapeutics position peaked at $24.1K in Q3 2025.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.